StairMed raises $48M Series B for focused ultrasound brain stimulation in China
Summary
Shanghai-based StairMed raised $48M in a Series B led by Qiming Venture Partners, with IDG Capital and Shenzhen Capital Group, to scale their non-invasive focused ultrasound neurostimulation devices across Chinese healthcare and wellness markets. StairMed's devices target depression, anxiety, and cognitive enhancement using transcranial focused ultrasound without implants or gel-based transducers.
Why it matters
StairMed's $48M Series B is one of the largest Chinese non-invasive neurotech rounds of 2025, reflecting growing domestic investment in neurological care solutions that do not depend on Western imports. China's regulatory framework for non-invasive neurostimulation is well-established and moving faster than for implantable devices.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial